Contents

1 Ankylosing Spondylitis as a Scientific Problem .......................... 1
   1.1 Ankylosing Spondylitis: An Introduction .......................... 1
   1.2 Clinical Features of Ankylosing Spondylitis ....................... 1
   1.3 Radiological Features of Ankylosing Spondylitis ................. 2
   1.4 The Disability of Ankylosing Spondylitis ......................... 3
   1.5 The Social and Financial Costs of Ankylosing Spondylitis ...... 3
   1.6 Molecular Mimicry and Rheumatic Fever ........................... 4
   1.7 The Properties of the Ankylosing Spondylitis Problem .......... 4
   1.8 King’s College Immunology Unit .................................. 5
   References .......................................................... 6

2 History of the Origin of Ankylosing Spondylitis ....................... 7
   2.1 Introduction ...................................................... 7
   2.2 Ankylosing Spondylitis and the Egyptian Pharaohs ................ 7
   2.3 Ankylosing Spondylitis in the Middle Ages ......................... 8
   2.4 Ankylosing Spondylitis and Realdo de Colombo .................... 8
   2.5 Connor’s Observations in France ................................ 8
   2.6 The Eighteenth Century in Europe ................................ 10
   2.7 The Nineteenth Century in London ................................ 10
   2.8 Bechterew in St. Petersburg ..................................... 10
   2.9 Strümpell in Erlangen and Berlin ................................ 11
   2.10 Pierre Marie and Léri in France .................................. 11
   2.11 Buckley’s Observations in the 1930s ............................ 11
   2.12 The Heart and Ankylosing Spondylitis ........................... 12
   2.13 Diagnostic Help from Physics .................................. 12
   2.14 Conclusion .................................................... 12
   References .......................................................... 12
3 The Discovery of HLA-B27 in Ankylosing Spondylitis and Related Disorders ............................................................... 15
3.1 The Tissue Typing Unit at the Westminster Hospital ........ 15
3.2 HLA-B27 in Ankylosing Spondylitis ................................. 15
3.3 Acute Anterior Uveitis and HLA-B27 .............................. 16
3.4 HLA-B27 in Reiter’s Disease and Reactive Arthritis .............. 16
3.5 HLA-B27 as the Predisposing Gene ................................. 17
3.6 Geography of HLA-B27 ................................................... 17
3.7 General Discussion and Conclusions ................................. 18
3.8 The Middlesex Hospital in London .................................... 18
3.9 The ‘Ankylosing Spondylitis Research Clinic of the Middlesex Hospital’ ............................................................... 19
References ........................................................................... 20

4 Molecular Mimicry Between HLA-B27 and Klebsiella Bacteria Investigated by Using Rabbit Antisera ......................................................... 23
4.1 Introduction: The Problem of HLA-B27 in Ankylosing Spondylitis . 23
4.2 Rabbit Immunisations ....................................................... 23
4.3 Immunodiffusion Experiments .......................................... 24
4.4 Haemagglutination Method ............................................... 25
4.5 Bacterial Agglutination ...................................................... 25
4.6 Radio-Binding Assay with Klebsiella Sonicate Preparation (KSP) ................................................................. 26
4.7 Lymphocytotoxicity Assay ................................................. 26
4.8 Results of Immunodiffusion Experiments ......................... 27
4.9 Haemagglutination Results .............................................. 28
4.10 Bacterial Agglutination Results ....................................... 29
4.11 Results of Radio-Binding Assay with Klebsiella Sonicate Preparation (KSP) ................................................................. 29
4.12 Cytotoxicity Results ....................................................... 30
4.13 Discussion and Conclusions ............................................. 31
References ........................................................................... 32

5 Molecular Mimicry Between HLA-B27 and Klebsiella Bacteria Investigated by Using Human Tissue Typing Sera ............... 35
5.1 Introduction: Molecular Mimicry and Tissue Typing Sera ....... 35
5.2 Bristol .............................................................................. 36
5.3 HLA Tissue Typing Sera .................................................... 36
5.4 Haemagglutination Method .............................................. 36
5.5 Labelling of Klebsiella Sonicate Preparation (KSP) ................. 36
5.6 Radio-Binding Assay for $^{125}$I-Klebsiella Sonicate Preparation ................................................................. 37
5.7 Competition Assay for $^{125}$I-Klebsiella Sonicate Preparation .... 37
5.8 Results of Haemagglutination Studies with HLA Typing Sera .... 38
5.9 Results of Radio-Binding Assay for $^{125}$I-Klebsiella Sonicate Preparation by HLA Typing Sera ......................................................... 38
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.10</td>
<td>Results of Competition Binding Assays</td>
<td>40</td>
</tr>
<tr>
<td>5.11</td>
<td>Discussion and Conclusions</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>43</td>
</tr>
<tr>
<td>6</td>
<td>Muscle Changes in Ankylosing Spondylitis</td>
<td>45</td>
</tr>
<tr>
<td>6.1</td>
<td>Introduction: Involvement of Muscle Pathology in Ankylosing Spondylitis</td>
<td>45</td>
</tr>
<tr>
<td>6.2</td>
<td>Muscle Stiffness, Muscle Pain and the Enthesis</td>
<td>45</td>
</tr>
<tr>
<td>6.3</td>
<td>Patients and Controls</td>
<td>46</td>
</tr>
<tr>
<td>6.4</td>
<td>Blood Samples, Muscle Biopsies and Histology</td>
<td>46</td>
</tr>
<tr>
<td>6.5</td>
<td>Muscle Strength and Electromyographic Studies</td>
<td>47</td>
</tr>
<tr>
<td>6.6</td>
<td>Results of Histological and Biochemical Investigations</td>
<td>47</td>
</tr>
<tr>
<td>6.7</td>
<td>Muscle Strength Measurements and Surface Electromyography</td>
<td>48</td>
</tr>
<tr>
<td>6.8</td>
<td>Pathological and Clinical Implications</td>
<td>49</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>50</td>
</tr>
<tr>
<td>7</td>
<td>Raised Serum IgA Is Present in Ankylosing Spondylitis Patients</td>
<td>51</td>
</tr>
<tr>
<td>7.1</td>
<td>Introduction: Immunoglobulin Levels and Disease Activity in Ankylosing Spondylitis</td>
<td>51</td>
</tr>
<tr>
<td>7.2</td>
<td>Ankylosing Spondylitis Patients and Controls</td>
<td>52</td>
</tr>
<tr>
<td>7.3</td>
<td>Methods Used in Estimating Serum Immunoglobulins</td>
<td>52</td>
</tr>
<tr>
<td>7.4</td>
<td>Results of Serum IgA Estimations</td>
<td>52</td>
</tr>
<tr>
<td>7.5</td>
<td>Results of Serum IgG Estimations</td>
<td>53</td>
</tr>
<tr>
<td>7.6</td>
<td>Results of Serum IgM Estimations</td>
<td>56</td>
</tr>
<tr>
<td>7.7</td>
<td>Discussion</td>
<td>57</td>
</tr>
<tr>
<td>7.8</td>
<td>Pathological and Clinical Implications</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>58</td>
</tr>
<tr>
<td>8</td>
<td>Faecal Cultures in Ankylosing Spondylitis and Uveitis</td>
<td>61</td>
</tr>
<tr>
<td>8.1</td>
<td>Introduction: The Origin of Ankylosing Spondylitis</td>
<td>61</td>
</tr>
<tr>
<td>8.2</td>
<td>Ankylosing Spondylitis Patients and Controls</td>
<td>62</td>
</tr>
<tr>
<td>8.2.1</td>
<td>Active Disease</td>
<td>62</td>
</tr>
<tr>
<td>8.2.2</td>
<td>Probably Active Disease</td>
<td>63</td>
</tr>
<tr>
<td>8.2.3</td>
<td>Inactive Disease</td>
<td>63</td>
</tr>
<tr>
<td>8.3</td>
<td>Collection and Investigations of Urinary and Faecal Specimens</td>
<td>63</td>
</tr>
<tr>
<td>8.4</td>
<td>Results of Urine Investigations</td>
<td>64</td>
</tr>
<tr>
<td>8.5</td>
<td>Results of Faecal Investigations</td>
<td>64</td>
</tr>
<tr>
<td>8.6</td>
<td>Acute Anterior Uveitis and Faecal Cultures</td>
<td>65</td>
</tr>
<tr>
<td>8.7</td>
<td>Results of Faecal Cultures in Patients with Uveitis</td>
<td>66</td>
</tr>
<tr>
<td>8.8</td>
<td>Discussion</td>
<td>66</td>
</tr>
<tr>
<td>8.9</td>
<td>Pathological and Clinical Implications</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>67</td>
</tr>
</tbody>
</table>
9 Biochemical Parameters and Klebsiella in Ankylosing Spondylitis
9.1 Introduction: The Use of Biochemical Parameters in Ankylosing Spondylitis
9.2 Selection of Ankylosing Spondylitis Patients and Controls
9.3 Assessment of Disease Activity
9.3.1 Active Disease
9.3.2 Probably Active Disease
9.3.3 Inactive Disease
9.4 Methods Used in These Studies
9.4.1 C-Reactive Protein Estimation
9.4.2 Erythrocyte Sedimentation Rate Measurement
9.4.3 Faecal Cultures
9.5 C-Reactive Protein and Disease Activity
9.6 Erythrocyte Sedimentation Rate and Disease Activity
9.7 Isolation of Klebsiella and Disease Activity
9.8 C-Reactive Protein and Erythrocyte Sedimentation Rate in Ankylosing Spondylitis Patients with and Without Klebsiella
9.9 Discussion
9.10 Pathological and Clinical Implications
References

10 Binding of Klebsiella Antisera to HLA-B27 Cells
10.1 Introduction: The Problem of HLA-B27 in Ankylosing and Its Link to Klebsiella
10.2 Patients and Control Subjects
10.3 Rabbit Antisera
10.4 Specificity Tests on Antisera
10.5 Enzyme Immunoassay to Investigate the Binding of Anti-Klebsiella Sonicate Preparation to HLA-B27 Lymphocytes
10.6 Absorption Experiments
10.7 Results of Antisera Specificity
10.8 Results of Enzyme Immunoassay and Absorption Experiments
10.9 Pathological and Clinical Implications
References

11 IgA Antibodies to Klebsiella and Other Gram-Negative Bacteria in Ankylosing Spondylitis
11.1 Introduction: The Problem of Elevated Serum IgA in Ankylosing Spondylitis and Its Link to Klebsiella
11.2 Selection of Serum Samples from Ankylosing Spondylitis Rheumatoid Arthritis, Psoriasis Patients and Healthy Controls
11.3 Enzyme-Linked Immunosorbent Assay (ELISA)
11.4 Absorption Studies
11.5 C-Reactive Protein Results
12 IgA Antibodies to *Klebsiella* Measured by Immunoblotting

12.1 Introduction: The Problem of Elevated Serum IgA in Ankylosing Spondylitis and Its Link to *Klebsiella*.

12.2 Selection of Serum Samples from Ankylosing Spondylitis, Rheumatoid Arthritis Patients and Healthy Controls.

12.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE).

12.4 Characteristics of the Four Study Groups.

12.5 Analysis of the Results of the Immunoblotting Assay.

12.6 Comparison of Serum and Synovial Fluids.

12.7 Pathological and Clinical Implications.

References.

13 Antibodies to *Klebsiella* in Ankylosing Spondylitis Measured by Bacterial Agglutination and ELISA Against Lipopolysaccharides.

13.1 Introduction: Gram-Negative Bacteria in Ankylosing Spondylitis.

13.2 First Study: Patients and Controls.

13.3 Statistical Analysis of Patient Groups and Controls.

13.4 Coombs Agglutination Assay.

13.5 Results of Coombs Agglutination Assay.

13.6 Second Study: Patients and Controls.

13.7 ELISA of Bacterial Lipopolysaccharide Samples.

13.8 Results of Study on Bacterial Lipopolysaccharides.

13.9 Clinical Implications and Discussion.

References.
14 Dutch and German Patients with Ankylosing Spondylitis
Have Antibodies to *Klebsiella* ........................................... 123
  14.1 The Netherlands Connection: An Introduction .................. 123
  14.2 Amsterdam: Location and History ................................. 123
  14.3 Patients and Controls ............................................. 124
  14.4 Serum C-Reactive Protein Levels ................................ 124
  14.5 Indirect Immunofluorescence Studies with *Klebsiella*
    in Ankylosing Spondylitis and Acute Anterior Uveitis Patients
    and *Proteus* in Rheumatoid Patients from the Netherlands ...... 125
    14.5.1 IgA Antibodies to *Klebsiella pneumoniae* .............. 126
    14.5.2 IgG Antibodies to *Proteus mirabilis* .................... 126
  14.6 German Studies on *Klebsiella* in Ankylosing Spondylitis .... 126
    14.6.1 Lübeck ................................................... 127
    14.6.2 Kiel .................................................... 129
  14.7 ELISA Studies on German Patients ............................... 129
  14.8 Clinical Implications and Conclusions ........................ 130
  14.9 Conclusions .................................................. 131
References ................................................................. 131

15 Spanish, Finnish and Swedish Patients with Ankylosing
Spondylitis Have Antibodies to *Klebsiella* .......................... 133
  15.1 The Spanish Connection: An Introduction ...................... 133
  15.2 Barcelona: Location and History ................................ 133
  15.3 Catalan Patients and Controls ................................ 134
  15.4 Statistical Analysis ............................................ 134
  15.5 Results on Catalan Patients ................................... 135
  15.6 Turku: The Finland Connection .................................. 136
  15.7 Results of Finnish Patients ................................... 136
  15.8 Uppsala and the Swedish Connection ......................... 137
  15.9 Swedish Studies ............................................... 138
  15.10 General Discussion and Conclusions ......................... 139
References ................................................................. 139

16 Molecular Mimicry Between *Klebsiella Pullulanase* Enzyme,
HLA-B27 and Collagens I and IV ........................................... 141
  16.1 Introduction: The Association of HLA-B27 with Ankylosing
    Spondylitis Is the Central Research Issue in This Disease ...... 141
  16.2 Computer Search for Other *Klebsiella* Proteins Cross-Reacting
    with HLA-B27 .................................................. 142
  16.3 Peptide ELISA Studies in Ankylosing Spondylitis Patients .... 143
    16.3.1 B*2705 Results ........................................ 144
    16.3.2 pulD Peptide Results ................................... 145
    16.3.3 Scrambled Control Peptide Results ...................... 146
  16.4 Pullulan and Pullulanase ...................................... 147
16.5 ELISA Studies on Effect of Antibody in Bacteria Grown in Presence or Absence of Pullulan .......................... 148
  16.5.1 Results of ELISA Studies in Ankylosing Spondylitis Patients ...................................................... 149
  16.5.2 Results of ELISA Studies in Rheumatoid Arthritis Patients .......................................................... 149
16.6 Serum Antibodies to the Pullulanase (pulA) Enzyme .......... 149
16.7 ELISA Studies on Collagen Types I and IV .................... 151
16.8 Discussion and Conclusions ......................................... 153
References ........................................................................ 157

17 Antibodies to Klebsiella and HLA-B27 Peptides in Ankylosing Spondylitis Patients from Southern Japan ....................... 159
  17.1 The Japanese Connection: An Introduction .................... 159
  17.2 Otsu: Location and History ........................................ 160
  17.3 Patients and Controls ................................................ 160
  17.4 Results of ELISA Studies on Bacteria ......................... 161
  17.5 Results of ELISA Studies on HLA-B27 and Pullulanase Peptide Sequences ......................................... 163
    17.5.1 Antibodies to the HLA-B27 Sequence ..................... 164
    17.5.2 Antibodies to the Pullulanase-D Peptide ................. 165
    17.5.3 Antibodies to Scrambled pulD Control Peptide .......... 167
  17.6 Discussion and Conclusions ....................................... 167
References ........................................................................ 169

18 Ankylosing Spondylitis Sera Are Cytotoxic to Cells Bearing HLA-B27 Sequences .................................................. 171
  18.1 Introduction: The Association of HLA-B27 with the Klebsiella Nitrogenase and Klebsiella Pullulanase Enzymes ....... 171
  18.2 Antibodies to Klebsiella Nitrogenase Reductase in Patients with Ankylosing Spondylitis .......................... 172
  18.3 Sera from Ankylosing Spondylitis and Rheumatoid Arthritis Patients ................................................. 173
  18.4 Synthetic Peptides and ELISA ..................................... 174
  18.5 Antibodies to Peptide Antigens in Ankylosing Spondylitis Patients ....................................................... 175
    18.5.1 Antibodies to the HLA-B27 Peptide ....................... 175
    18.5.2 Antibodies to the Klebsiella pneumoniae Nitrogenase Peptide .................................................... 175
    18.5.3 Antibodies to the Klebsiella pneumoniae Pullulanase Peptide ....................................................... 175
  18.6 Antibodies to Peptide Antigens in Rheumatoid Arthritis Patients ......................................................... 176
    18.6.1 HLA-DRB1*0404 Peptide ..................................... 176
18.6.2 *Proteus mirabilis* Haemolysin Peptide .................. 176
18.6.3 Type XI Collagen Peptide ................................. 176
18.7 Preparation of Sheep Red Blood Cells for Cytotoxicity Assay ......................................................... 177
18.8 Cytotoxicity Studies in Ankylosing Spondylitis Patients ...... 178
18.9 Cytotoxicity Studies in Rheumatoid Arthritis Patients ....... 179
  18.9.1 EQRRAA Peptide .............................................. 179
  18.9.2 LRREI Peptide ................................................. 180
  18.9.3 EDERAA Peptide .............................................. 181
18.10 Discussion and Conclusions ................................... 181
References ..................................................................... 184

19 Pathogenesis of Ankylosing Spondylitis and *Klebsiella Substrates* ......................................................... 187
  19.1 Introduction: The Association of Serum IgA in Ankylosing Spondylitis Points to a Bowel Microbe 187
  19.2 Marseille: Location and History ................................ 190
  19.3 Lymphangiographic Studies ...................................... 190
  19.4 The Proposed Model for the Pathogenesis of Ankylosing Spondylitis .............................................. 191
  19.5 Importance for Early Diagnosis of Ankylosing Spondylitis .... 194
  19.6 The Concept of ‘Gram-Negative Reactive Arthritis’ and HLA-B27 ......................................................... 194
    19.6.1 Paronen’s Study ............................................... 194
    19.6.2 The ‘USS Little Rock’ Epidemic ............................ 195
    19.6.3 *Salmonella* Reactive Arthritis in Finland .......... 195
    19.6.4 *Yersinia* Reactive Arthritis ................................ 195
  19.7 Starch as the Source of the Main Bacterial Substrate in the Gut .............................................................. 196
    19.7.1 A Patient Provides an Important Clue ................. 196
    19.7.2 Fecal Flora in Vegetarian Seventh Day Adventists ........ 196
    19.7.3 Carbohydrates as Bacterial Substrates ............... 197
    19.7.4 Ileostomy Studies .............................................. 197
    19.7.5 Oral Hydrogen Excretion Studies .......................... 197
  19.8 Composition of the ‘Low Starch Diet’ .......................... 200
  19.9 Discussion and Conclusions ................................... 200
References ..................................................................... 202

20 Ankylosing Spondylitis and the ‘Low-Starch Diet’ .......... 203
  20.1 Introduction: The Therapeutic Imperative .................... 203
  20.2 Current Therapeutic Interventions ............................ 203
    20.2.1 Physiotherapy and Exercise ............................... 203
    20.2.2 Sulphasalazine ................................................. 204
    20.2.3 Sulphasalazine and *Klebsiella* ....................... 204
    20.2.4 Moxifloxacin in Ankylosing Spondylitis ................ 204
References ..................................................................... 204
20.3  ‘Low-Starch Diet’ in Controls ............................................. 205
20.3.1 Open Study with 21 Healthy Controls ............................. 205
20.3.2 Nutritionally Controlled Study with
11 Healthy Subjects .............................................................. 205
20.4  The ‘Low-Starch Diet’ in Ankylosing Spondylitis Patients ...... 207
20.4.1 How Not to Do ‘Coded Runs’ Involving Diet
Modification ................................................................. 207
20.4.2 Ankylosing Spondylitis Patients Partaking
in the Diet Study ............................................................. 209
20.4.3 Erythrocyte Sedimentation Rate and Haemoglobin
Correlation ................................................................. 209
20.4.4 C-Reactive Protein and Haemoglobin Correlation ......... 209
20.5  ‘Low-Starch Diet’ and Levels of Inflammation in Ankylosing
Spondylitis Patients on the Diet ............................................. 211
20.6  Discussion and Conclusions ............................................ 211
20.7  A Patient Followed for 28 years. (Mrs. Beard’s Story) .......... 215
20.8  A Sceptic Tries the ‘Low-Starch Diet’ (George’s Story) ....... 217
20.9  Carol Sinclair and Her Book The IBS Low-Starch Diet .......... 218
References ............................................................................ 219

21  The Problem of Crohn’s Disease and Klebsiella ......................... 221
21.1  Introduction: Crohn’s Disease ........................................... 221
21.2  Ghent: Location and History ............................................ 221
21.3  The Link Between Ankylosing Spondylitis and Crohn’s Disease 222
21.4  Birmingham: Location and History .................................... 222
21.5  Antibodies to Yersinia and Klebsiella but Not Pseudomonas
in Crohn’s Disease Patients .................................................. 223
21.6  IBD Patients from the Royal Free Hospital in London Have
Antibodies to Klebsiella .......................................................... 223
21.7  Coeliac Disease Patients from St. Thomas’ Hospital Do
Not Have Antibodies Against Klebsiella ................................. 224
21.8  Antibodies to Klebsiella in Crohn’s Disease and in Ankylosing
Spondylitis Patients from Scotland ........................................ 229
21.8.1 Glasgow ................................................................. 230
21.8.2 Edinburgh ............................................................... 230
21.9  Immune Response to Collagens in Patients with Crohn’s Disease
and Ankylosing Spondylitis .................................................. 231
21.10 Conclusion: Crohn’s Disease Is Caused by Klebsiella
in HLA-B27 Negative Individuals .......................................... 233
References ............................................................................ 234

22  Ankylosing Spondylitis and ‘Popper Sequences’ ....................... 235
22.1  Introduction to ‘Popper Sequences’ .................................... 235
22.2  Components of a ‘Popper Sequence’ ................................. 236
22.3 First Popper Sequence ........................................ 236
22.4 Second Popper Sequence ...................................... 237
22.5 Third Popper Sequence ........................................ 238
22.6 Fourth Popper Sequence ....................................... 239
22.7 Fifth Popper Sequence .......................................... 240
22.8 Sixth Popper Sequence .......................................... 241
22.9 Seventh Popper Sequence ...................................... 242
22.10 Eighth Popper Sequence ....................................... 243
22.11 Ninth Popper Sequence ........................................ 244
22.12 Tenth Popper Sequence ........................................ 245
22.13 Eleventh Popper Sequence .................................... 246
22.14 Twelfth Popper Sequence ..................................... 247
22.15 Thirteenth Popper Sequence .................................. 248
22.16 Therapeutic Implications ..................................... 249
References ............................................................. 249

Index ................................................................. 251
Ankylosing spondylitis and Klebsiella
Ebringer, A.
2013, XX, 256 p., Hardcover
ISBN: 978-1-4471-4299-7